ArticlePloS one2013
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Changes in Tissue Fluidity Predict Tumor Aggressiveness In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Pooled it
- Article
- Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.Therapeutic advances in medical oncology · 2026Article
- Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence.International journal of breast cancer · 2026Article
- The Role of Molecular Profiling in De-Escalation of Toxic Therapy in Breast Cancer.International journal of molecular sciences · 2025Review
- A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.Breast cancer research : BCR · 2024Article
- ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin.NPJ breast cancer · 2022Article
- Molecular Drivers of OncoJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.Cancer medicine · 2020Article
- Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.Annals of surgical oncology · 2020Article
- Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.Breast (Edinburgh, Scotland) · 2020Article
- Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.BMC cancer · 2019Article
- Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.BMC cancer · 2019Article
- Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?Cancer management and research · 2019Review
- Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.Frontiers in oncology · 2019Article
- A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.Frontiers in oncology · 2019Article
- Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients.Oncotarget · 2018Article
- Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.Asia-Pacific journal of clinical oncology · 2018Article
- Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.PloS one · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSeveral multigene expression-based tests offering prognostic and predictive information in hormone-receptor positive early breast cancer were established during the last years. These tests provide prognostic information on distant recurrences and can serve as an aid in therapy decisions. We analyzed the recently validated reverse-transcription-quantitative-real-time PCR-based multigene-expression Endopredict (EP)-test on 34 hormone-receptor positive breast-cancer cases and compared the EP scores with the Oncotype DX Recurrence-scores (RS) obtained from the same cancer samples.
methodsFormalin-fixed, paraffin-embedded invasive breast-cancer tissues from 34 patients were analyzed by the EP-test. Representative tumor blocks were analyzed with Oncotype DX prior to this study. Tumor tissue was removed from unstained slides, total-RNA was isolated and EP-analysis was performed blinded to Oncotype DX results.
resultsExtraction of sufficient amounts of RNA and generation of valid EP-scores were possible for all 34 samples. EP classified 11 patients as low-risk and 23 patients as high-risk. RS Score defined 15 patients as low-risk, 10 patients as intermediate-risk in and 9 patients as high-risk. Major-discrepancy occurred in 6 of 34 cases (18%): Low-risk RS was classified as high-risk by EP in 6 cases. Combining the RS intermediate-risk and high-risk groups to a common group, the concordance between both tests was 76%. Correlation between continuous EP and RS-scores was moderate (Pearson-coefficient: 0.65 (p<0.01).
conclusionWe observed a significant but moderate concordance (76%) and moderate correlation (0.65) between RS and EP Score. Differences in results can be explained by different weighting of biological motives covered by the two tests. Further studies are needed to explore the clinical relevance of discrepant test results with respect of outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.